Relapse of Ulcerative Colitis with Immune Thrombocytopenia and Pyoderma Gangrenosum Subsequent to Receiving COVID-19 Vaccination.
Kohei SuzukiMasato AizawaKana TamazawaKenta UedaJun WadaYuki NakajimaGoro ShibukawaShohei IkedaSaburo TsunodaKazutomo TogashiPublished in: Internal medicine (Tokyo, Japan) (2024)
This case illustrates the complex interactions of the immune responses after vaccination and highlights their potential connections to various autoimmune conditions. A 22-year-old man with quiescent ulcerative colitis (UC) presented with abdominal pain, rectal bleeding, and thrombocytopenia 7 days after receiving the third coronavirus disease 2019 mRNA vaccination. Laboratory data confirmed the diagnosis of immune thrombocytopenia. High-dose intravenous immunoglobulin administration boosted the patient's platelet count. Simultaneously, colonoscopy revealed that his UC had relapsed. Although salazosulfapyridine briefly improved his symptoms, his stool frequency worsened one week later. The patient also developed pyoderma gangrenosum. Subsequent treatment with infliximab notably improved both pyoderma gangrenosum and UC.
Keyphrases
- ulcerative colitis
- coronavirus disease
- high dose
- abdominal pain
- immune response
- case report
- sars cov
- acute lymphoblastic leukemia
- low dose
- stem cell transplantation
- respiratory syndrome coronavirus
- acute myeloid leukemia
- multiple sclerosis
- randomized controlled trial
- rectal cancer
- clinical trial
- diffuse large b cell lymphoma
- electronic health record
- big data
- hodgkin lymphoma
- deep learning
- inflammatory response
- artificial intelligence
- single cell
- sleep quality
- climate change
- replacement therapy
- free survival